<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute ST-elevation myocardial infarction: Management of anticoagulation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute ST-elevation myocardial infarction: Management of anticoagulation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute ST-elevation myocardial infarction: Management of anticoagulation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">A Michael Lincoff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Freek Verheugt, MD, FACC, FESC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute myocardial infarction (MI) results from rupture or erosion of an atherosclerotic plaque, which leads to intraluminal thrombosis, reduced distal blood flow, and myocardial ischemia or infarction. Intraluminal hemostasis is a dynamic process involving both clot formation and fibrinolysis. The goal of antithrombotic therapy (the combination of anticoagulant and antiplatelet therapy) is to prevent clot extension and clot reformation. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and  <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">"Mechanisms of acute coronary syndromes related to atherosclerosis"</a>.)</p><p>This topic will review the approach to anticoagulation in patients with acute ST-elevation MI (STEMI) and will provide recommendations for the use of specific anticoagulants according to whether the patient will receive primary percutaneous coronary intervention (PCI), primary fibrinolysis, or no reperfusion therapy.</p><p>Information regarding anticoagulant agents in non-ST-elevation acute coronary syndromes (unstable angina or non-STEMI) and the role of antiplatelet therapy in STEMI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLASSIFICATION OF ANTICOAGULANT AGENTS</span><span class="headingEndMark"> — </span>There are three classes of anticoagulants that are used to treat acute coronary syndromes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparins</strong> – The heparins, including <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) and the low molecular weight heparins (LMWHs), form complexes with antithrombin (AT, formerly known as AT III) that convert AT from a slow to a rapid inactivator of thrombin (ie, indirect thrombin inhibition) and factor Xa. To a lesser extent, the heparins also inactivate factors XIIa, XIa, and IXa. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis"</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unfractionated heparin</strong> – Intravenous UFH induces rapid anticoagulation but binds to circulating plasma proteins, which results in variable inter- and intrapatient effects that require frequent monitoring and dose adjustments. UFH is more likely to cause heparin-induced thrombocytopenia compared with other anticoagulants. (See  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low molecular weight heparin</strong> – Similar to UFH, LMWH inactivates factor Xa but has less effect on thrombin  (<a class="graphic graphic_figure graphicRef101832" href="/z/d/graphic/101832.html" rel="external">figure 1</a>). LMWH has a more predictable anticoagulant effect when compared with UFH and is less likely to cause immune-mediated thrombocytopenia. The anticoagulant effect of LMWH is more difficult to monitor; LMWH does not prolong the activated partial thromboplastin time in a predictable fashion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Synthetic heparin</strong> – The synthetic heparin pentasaccharide <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> acts through antithrombin to exclusively neutralize factor Xa. Fondaparinux is the only nonheparin factor Xa inhibitor that has been evaluated for efficacy and safety in patients with STEMI. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct factor Xa inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct thrombin inhibitors</strong> – The direct thrombin inhibitors (eg, <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a>, inogatran, efegatran, lepirudin, hirudin, and <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> [Hirulog]) directly bind to and inactivate one or more of the active sites on the thrombin molecule [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct thrombin inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H3934220690"><span class="h1">PRIMARY PERCUTANEOUS CORONARY INTERVENTION</span></p><p class="headingAnchor" id="H3194085896"><span class="h2">Anticoagulation prior to PCI</span><span class="headingEndMark"> — </span>Patients with STEMI whose reperfusion strategy is primary percutaneous coronary intervention (PCI)  (<a class="graphic graphic_algorithm graphicRef138821" href="/z/d/graphic/138821.html" rel="external">algorithm 1</a>) require prompt anticoagulation  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>). The only exceptions to immediate anticoagulation are cases in which the process of starting anticoagulation would delay primary PCI (eg, delay transfer to a PCI-capable center, delay the PCI procedure).</p><p>For most patients with STEMI who will undergo primary PCI, we suggest initial anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) rather than other agents (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>).</p><p>Other factors that affect the approach to anticoagulation include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic oral anticoagulation</strong> – In patients who take oral anticoagulants, we typically anticoagulate with an intravenous (IV) agent. There are no data to suggest that outpatient anticoagulation (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, direct oral anticoagulants) is sufficient anticoagulation for PCI in patients with STEMI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin-induced thrombocytopenia</strong> – In patients with a history of heparin-induced immune thrombocytopenia, we anticoagulate with <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>, which is started in the catheterization suite. (See <a class="local">'Anticoagulation during PCI'</a> below.)</p><p></p><p>In brief, this approach to anticoagulation prior to PCI is based on the requirement for anticoagulation during PCI to prevent catheter-associated thrombi, the desire to slow the progression of thrombus formation without specific evidence of efficacy during the typically short interval between initiating anticoagulation and undergoing PCI, the available trial data that suggest a similar effect of the available anticoagulants, and the safety of UFH in terms of dosing and monitoring during PCI. Further details of the rationale and supporting trials are described elsewhere in this topic. (See <a class="local">'Evidence in primary PCI'</a> below.)</p><p class="headingAnchor" id="H1767423023"><span class="h2">Anticoagulation during PCI</span><span class="headingEndMark"> — </span>All patients who undergo PCI require anticoagulation to prevent intraarterial thrombus formation. During PCI for STEMI, we suggest UFH or <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> rather than other anticoagulants (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>). The choice between UFH and bivalirudin is individualized and is largely based on the cardiologist’s preference (eg, UFH is easier to monitor than bivalirudin, bivalirudin requires a longer duration of infusion than UFH)  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>).</p><p>If <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> was given &gt;6 hours prior to PCI, we initiate UFH during PCI rather than maintain anticoagulation with enoxaparin.</p><p>If not given prior to PCI, the chosen agent is either started or additional doses are given to achieve appropriate levels of anticoagulation in the catheterization suite. (See <a class="local">'Dosing and monitoring'</a> below.)</p><p>In summary, anticoagulation is required to prevent intraarterial thrombi associated with catheters and equipment used during PCI. Both UFH and <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> are effective and can be safely administered to patients with STEMI. We do not favor the use of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>; it has complex dosing and is difficult to monitor. We do not use <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in this setting; low-quality data suggest that fondaparinux may increase the risk of catheter thrombi and adverse coronary artery events (eg, acute vessel closure). (See <a class="local">'Evidence in primary PCI'</a> below.)</p><p class="headingAnchor" id="H1235664789"><span class="h2">Anticoagulation after PCI</span><span class="headingEndMark"> — </span>For patients with acute coronary syndrome who undergo PCI, including patients with STEMI, the role of routine use of anticoagulant therapy after PCI is unclear. The duration of anticoagulation is influenced by the agent used, whether complications occurred during PCI, and whether there is a clear indication for long-term anticoagulation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without complications or other indications for anticoagulation</strong> – In patients who have an uncomplicated PCI and who do not have another indication for anticoagulation (eg, atrial fibrillation, mechanical heart valve), UFH or <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> can be stopped immediately following the procedure, while <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> is typically continued for four hours after PCI.</p><p></p><p class="bulletIndent1">This approach is based on the use of UFH and low molecular weight heparin (LMWH) in large randomized trials and from the results of a trial that compared no <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> after PCI with four hours of bivalirudin infusion after PCI; the latter trial found similar rates of the primary outcome [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with complications of PCI</strong> –<strong> </strong>In patients who have evidence of bleeding or thrombosis or who are at risk of these complications, anticoagulation is managed as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bleeding complications</strong> – In patients with major access site bleeding or other clinically significant bleeding (eg, intracerebral hemorrhage, hemorrhagic pericardial effusion) that may be worsened by continued anticoagulation, additional management of anticoagulation and bleeding may be required. The management of these patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic complications</strong> – Thrombotic complications of STEMI that would require extending the duration of anticoagulation are rare. In cases of residual intracoronary thrombus or other thrombotic complications, treatment with additional anticoagulation or antiplatelet therapy is individualized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other indications for long-term anticoagulation</strong> –<strong> </strong>In patients who have other indications for anticoagulation (eg, evidence of left ventricular thrombus, atrial fibrillation), we continue parenteral anticoagulation until the patient can be transitioned to an anticoagulant appropriate for outpatient use. The disease or condition under treatment determines the agent of choice. Common conditions that may require anticoagulation in patients with STEMI include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Left ventricular thrombus. (See  <a class="medical medical_review" href="/z/d/html/90.html" rel="external">"Left ventricular thrombus after acute myocardial infarction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atrial fibrillation. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deep vein thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical valve prosthesis. (See  <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p></p><p class="headingAnchor" id="H702984422"><span class="h2">Dosing and monitoring</span><span class="headingEndMark"> — </span>The dosing and monitoring of the most common anticoagulants used during PCI for STEMI are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unfractionated heparin</strong> –<strong> </strong>The dosing and monitoring of UFH therapy depends on the venue of care and the proximity to the PCI procedure:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initiating and monitoring UFH</strong> – For patients who will undergo PCI without use of a glycoprotein (GP) IIb/IIIa inhibitor, which is our preferred approach, we use an initial IV bolus of UFH of 70 to 100 units/kg up to a maximum of 10,000 units (with additional boluses if needed to achieve an activated clotting time [ACT] target &gt;250 s).</p><p></p><p class="bulletIndent2">For patients who will undergo PCI with a GP IIb/IIIa inhibitor, which is not our usual approach, we use an initial UFH bolus of 50 to 70 units/kg up to a maximum of 7000 units (with additional boluses if needed to achieve an ACT target &gt;200 s).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Managing UFH in the emergency department or after PCI</strong> – For most patients, the expected interval between initiation of UFH and transfer to the catheterization laboratory is short (eg, less than 90 minutes) and accordingly, monitoring is not required prior to PCI. However, if there is a longer delay prior to PCI or if UFH is continued after PCI, UFH should be dosed and monitored in accordance with local protocols (eg, nomograms) specific to the indication for treatment. (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Unfractionated heparin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bivalirudin</strong> – We use an initial bolus of 0.75 mg/kg followed by an IV infusion of 1.75 mg/kg/hour for two to four hours after PCI [<a href="#rid3">3</a>]. The maintenance dose is decreased to 1.0 mg/kg/hour in patients with an estimated glomerular filtration rate (eGFR) &lt;30 mL/1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> is not typically monitored during the PCI procedure, though one contributor to this topic obtains a single activated clotting time assay to ensure that delivery of bivalirudin was effective.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enoxaparin</strong> – LMWHs are managed by weight-based dosing, and monitoring is typically not required. <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> is the LMWH of choice for use in acute coronary syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initiating </strong><strong>enoxaparin</strong><strong> in the emergency department</strong> – The initial dose of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> is adjusted for age and renal function, specifically creatinine clearance. However, PCI should not be delayed by blood sampling or waiting for the return of a creatinine level.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age less than 75 years</strong> – In patients who are &lt;75 years of age with creatinine clearance ≥30 mL/minute using the Cockcroft-Gault formula (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>), we use a loading dose of 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (maximum of 100 mg for the first two doses only). The first subcutaneous dose should be administered with the IV bolus.</p><p></p><p class="bulletIndent3">For patients who are &lt;75 years of age with a creatinine clearance &lt;30 mL/minute using the Cockcroft-Gault formula, we use a 30 mg IV bolus given with the first dose of the subcutaneous maintenance regimen, which is adjusted to 1 mg/kg subcutaneously every 24 hours.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age ≥75 years</strong> – In patients ≥75 years of age with creatinine clearance ≥30 mL/minute, we do not use a loading dose and administer a maintenance dose of 0.75 mg/kg subcutaneously every 12 hours (maximum of 75 mg for the first two doses only).</p><p></p><p class="bulletIndent3">For patients who are 75 years of age or older with a creatinine clearance &lt;30 mL/minute, we do not use a loading dose and administer a maintenance subcutaneous dose of 1 mg/kg every 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing </strong><strong>enoxaparin</strong><strong> during PCI</strong> – Due to the complexity of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> dosing, for most patients who were initially treated with enoxaparin and in whom the last dose was given more than six hours prior to PCI, we change from enoxaparin- to UFH-based anticoagulation at the beginning of PCI.</p><p></p><p class="bulletIndent2">In patients who will continue with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> anticoagulation, several factors influence the choice of dosing of enoxaparin during PCI:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Last dose given less than eight hours prior to PCI</strong> –<strong> </strong>If the last dose of subcutaneous <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> was given within the prior eight hours, no additional enoxaparin should be given prior to PCI.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Last dose given 8 to 12 hours before PCI</strong> –<strong> </strong>If <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> will be continued and the last subcutaneous dose was given 8 to 12 hours prior to PCI, an IV dose of 0.3 mg/kg of enoxaparin should be given prior to PCI [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Last dose given more than 12 hours prior to PCI</strong> – If the last dose of subcutaneous <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> was given more than 12 hours prior to PCI, another full dose of enoxaparin is given immediately prior to PCI.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing for prolonged PCI procedures</strong> – For patients undergoing primary PCI whose PCI procedure has extended over 120 minutes, an IV bolus of 0.25 mg/kg should be given.</p><p></p><p class="headingAnchor" id="H1816143260"><span class="h2">Evidence in primary PCI</span><span class="headingEndMark"> — </span>It is standard practice to give anticoagulation during PCI to prevent thrombus formation on intravascular devices (eg, arterial sheaths, catheters, stents). Our preference for the use of UFH in most patients is based on clinical trial evidence that shows similar efficacy between UFH and other anticoagulants and our experience with the dosing and monitoring of UFH, which is simpler than that of other anticoagulants. In addition, lower-quality data (eg, subgroup analyses, secondary endpoint analyses) suggest that UFH may be associated with a higher rate of bleeding and a lower rate of definite stent thrombosis when compared with <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> and with a lower rate of equipment thrombosis when compared with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>.</p><p>Our approach to the timing of anticoagulation, dosing, and duration of therapy is derived from trial protocols and agrees with the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines [<a href="#rid4">4-6</a>].</p><p>The evidence includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH compared with </strong><strong>bivalirudin</strong> – The trials that examined the relative efficacy of UFH and <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> under conditions similar to our practice (ie, rare treatment with a GP IIb/IIIa inhibitor, routine use of <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>, routine use of radial access) have arrived at differing conclusions. In aggregate, these trials suggest that the clinical efficacy of UFH and bivalirudin are likely similar. Pretreatment with prasugrel or ticagrelor at least one hour prior to PCI may affect the relative efficacy of UFH and bivalirudin, but there is no rigorous comparison of anticoagulants based on specific P2Y<sub>12</sub> pretreatment regimens. The trials that compare UFH and bivalirudin include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial (BRIGHT-4) that included 6016 patients with STEMI who underwent PCI via radial access and who were assigned to treatment with either <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> before and after PCI or to a single dose of UFH before PCI, the risk of mortality was lower with bivalirudin (3 versus 4 percent; hazard ratio [HR] 0.75, 95% CI 0.57-0.99) and the rate of recurrent MI was similar between the two groups (0.6 versus 0.8 percent) [<a href="#rid3">3</a>]. The rate of Bleeding Academic Research Consortium (BARC) grade 2 to 5 bleeding events was similar in the bivalirudin group (2.1 versus 2.6 percent; HR 0.82, 95% CI 0.59-1.14). However, these small differences in efficacy and safety are of unclear clinical significance. In addition, it was unclear whether patients in the trial were pretreated with either <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> at least one hour prior to PCI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the 2017 SWEDEHEART trial, 6006 patients with STEMI or non-STEMI undergoing urgent PCI were randomly assigned to <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> or UFH [<a href="#rid7">7</a>]. Most patients received radial artery access; the use of GP IIb/IIIa inhibitors was rare (2.4 and 2.8 percent of patients in the bivalirudin and heparin groups, respectively), and pretreatment one hour prior to PCI with either <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> (required per protocol) occurred in 60 percent of patients.</p><p></p><p class="bulletIndent2">The primary composite endpoint (death from any cause, MI, or major bleeding at 180 days) occurred in 12.3 percent in the <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> group and 12.8 percent in the heparin group (HR 0.96, 95% CI 0.83-1.10). While not powered to assess the individual endpoints that comprised the composite outcome, the trial did not find large differences between the two anticoagulants for the individual components. The rate of stent thrombosis was similar between the two groups (1.7 versus 1.8 in the UFH group). The rates of the primary outcome were similar in patients with radial or femoral access, and a subgroup analysis did not detect important differences between UFH and bivalirudin based on the time from P2Y<sub>12</sub> inhibitor dose to PCI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the 2014 HEAT-PPCI single-center trial, 1829 patients undergoing emergency angiography were randomly assigned to heparin (70 units/kg) or <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> (bolus 0.75 mg/kg; infusion 1.75 mg/kg/hour) [<a href="#rid8">8</a>]. The rate of GP IIb/IIIa inhibitor use was similar between the two groups (13 and 15 percent, respectively). <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a> or <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> was used in nearly 90 percent of patients. Approximately 80 percent of patients received a radial artery approach for vascular access.</p><p></p><p class="bulletIndent2">The primary outcome included all-cause mortality, cerebrovascular accident, reinfarction, or additional unplanned target lesion revascularization and occurred more often in the <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> group (8.7 versus 5.7 percent; relative risk [RR] 1.52, 95% CI 1.1-2.1). Rates of major bleeding were similar in the bivalirudin and heparin groups (3.5 versus 3.1 percent, respectively; RR 1.2, 95% CI 0.7-1.9). Definite or probable stent thrombosis occurred more often with bivalirudin (3.4 versus 0.9 percent; RR 3.91, 95% CI 1.6-9.5). In a prespecified subgroup analysis, radial and femoral access had a similar risk of the primary outcome.</p><p></p><p class="bulletIndent1">While there are older trials that compared the efficacy of UFH with <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>, their results are less pertinent to modern practice, in which radial access is common, <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> are used more commonly than <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, and GP IIb/IIIa inhibitor use is rare [<a href="#rid2">2,9,10</a>]. In aggregate, these older trials suggested that the risk of mortality and recurrent MI were similar with UFH and bivalirudin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH compared with </strong><strong>enoxaparin</strong> – There are few high-quality trials that compared UFH with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the only trial (ATOLL) of patients with STEMI that compared UFH with intravenous <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, 80 percent of patients received a GP IIb/IIIa inhibitor, 93 percent received <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, and 67 percent of patients underwent radial access [<a href="#rid11">11</a>]. At 30 days, the group assigned to enoxaparin had a nonsignificantly lower risk of death, complications of MI, procedure failure, or major bleeding (28 versus 34 percent; RR 0.83, 95% CI 0.68-1.01); the rates of major bleeding were similar between the two groups.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two meta-analyses (one of which included ATOLL) concluded that the use of LMWH (generally <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>) compared with UFH leads to lower rates of mortality and major bleeding [<a href="#rid12">12,13</a>]. However, important limitations of these meta-analyses limit their application to practice and include pooling of trials and observational studies, absence of patient level data, and variation in the timing, dose, and route of administration of enoxaparin across studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH compared with </strong><strong>fondaparinux</strong> – Our preference for UFH rather than <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is based on subgroup analyses of the OASIS-6 trial [<a href="#rid14">14</a>]. In the subgroup of patients in the trial who underwent PCI, random assignment to fondaparinux or UFH was associated with similar rates of death and reinfarction, but patients who received fondaparinux had higher rates of guiding catheter thrombosis (22 versus 0; p&lt;0.001) and higher rates of coronary complications such as abrupt coronary artery closure, new angiographic thrombus, catheter thrombus, no reflow, dissection, or perforation (270 versus 225; p = 0.04). Though these analyses are not conclusive, the similar efficacy of fondaparinux and UFH in patients undergoing PCI and the possibility of higher equipment thrombus rates and coronary artery complications lead us to favor UFH over fondaparinux.</p><p></p><p class="bulletIndent1">The full results of the complex OASIS-6 trial and its subsequent analyses are discussed elsewhere in this topic. (See <a class="local">'Rationale and evidence in primary fibrinolysis'</a> below.)</p><p></p><p class="headingAnchor" id="H21645429"><span class="h1">FIBRINOLYTIC THERAPY WITH OR WITHOUT PLANNED PCI</span></p><p class="headingAnchor" id="H2877107188"><span class="h2">Choice of anticoagulant</span><span class="headingEndMark"> — </span>In patients with STEMI who undergo reperfusion with fibrinolysis, and regardless of the specific fibrinolytic agent chosen, the approach to anticoagulation is influenced by the likelihood of angiography and/or percutaneous coronary intervention (PCI) following fibrinolysis  (<a class="graphic graphic_algorithm graphicRef138821" href="/z/d/graphic/138821.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>), as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinolysis followed by PCI</strong> – In patients who undergo primary fibrinolysis and who are likely to have PCI thereafter (ie, pharmacoinvasive strategy), we suggest the use of <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) rather than other agents (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>, or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>).</p><p></p><p class="bulletIndent1">This approach is influenced by the similar efficacy of the anticoagulants in fibrinolysis and our preference for UFH in patients undergoing PCI. (See <a class="local">'Anticoagulation during PCI'</a> above and <a class="local">'Rationale and evidence in primary fibrinolysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinolysis without planned PCI</strong> – For patients who are unlikely to undergo angiography or PCI, we suggest anticoagulation with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> rather than other agents or no anticoagulation. However, fondaparinux is not approved for use in patients with STEMI by the US Food and Drug Administration.</p><p></p><p class="bulletIndent1">Our approach is supported by evidence that suggest that <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> and <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> have favorable effects when compared with no anticoagulation and that these agents are superior to UFH. The rationale and evidence for this approach are discussed elsewhere in this topic. (See <a class="local">'Rationale and evidence in primary fibrinolysis'</a> below.)</p><p></p><p class="headingAnchor" id="H3598574862"><span class="h2">Dosing and duration of therapy</span><span class="headingEndMark"> — </span>In patients who will undergo primary fibrinolysis, the dosing and duration of anticoagulant therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH</strong> – For patients receiving fibrinolysis, we suggest an initial intravenous (IV) bolus dose of UFH of 60 units/kg (maximum of 4000 units) followed by an IV infusion of 12 units/kg/hour (maximum 1000 units/hour) to achieve an activated partial thromboplastin time of 50 to 70 s.</p><p></p><p class="bulletIndent1">The infusion is maintained with periodic monitoring according to local protocols until PCI is complete or for 48 hours, whichever comes first.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enoxaparin</strong> – The dose of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> is based on age and kidney function, but assessment of kidney function should not delay the delivery of anticoagulation and fibrinolysis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age less than 75 years</strong> –<strong> </strong>In patients who are &lt;75 years of age with creatinine clearance ≥30 mL/minute using the Cockcroft-Gault formula (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>), we use a loading dose of 30 mg plus 1 mg/kg (maximum of 100mg). The maintenance dose is 1 mg/kg given subcutaneously every 12 hours (maximum of 100 mg for the first maintenance dose).</p><p></p><p class="bulletIndent2">For patients who are &lt;75 years of age with a creatinine clearance &lt;30 mL/minute using the Cockcroft-Gault formula, we use a 30 mg IV bolus given with the first dose of the subcutaneous maintenance regimen, which is adjusted to 1 mg/kg subcutaneously every 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age ≥75 years</strong> – In patients ≥75 years with creatinine clearance ≥30 mL/minute, we do not use a loading dose and administer a maintenance dose of 0.75 mg/kg subcutaneously every 12 hours (maximum of 75 mg for the first two doses only).</p><p></p><p class="bulletIndent2">For patients who are 75 years or older with a creatinine clearance &lt;30 mL/minute, we do not use a loading dose and administer a maintenance subcutaneous dose of 1 mg/kg every 24 hours.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">Enoxaparin</a> therapy is continued until PCI occurs, until discharge, or for eight days, whichever comes first. At the time of PCI, enoxaparin is typically switched to UFH (see <a class="local">'Anticoagulation during PCI'</a> above). After PCI, enoxaparin is discontinued unless there is another indication for ongoing anticoagulation (eg, left ventricular thrombus, atrial fibrillation).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fondaparinux</strong> – For patients receiving fibrinolytic therapy who have a creatinine clearance &gt;30 mL/minute, we give <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> 2.5 mg intravenously as a bolus followed by a subcutaneous dose of 2.5 mg once daily. Fondaparinux should not be used in patients with an estimated creatinine clearance &lt;30 mL/minute.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">Fondaparinux</a> should be continued until discharge or for eight days, whichever comes first.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Rationale and evidence in primary fibrinolysis</span><span class="headingEndMark"> — </span>In patients undergoing primary fibrinolysis, the rationale and evidence for anticoagulation depend on whether PCI is likely or unlikely after fibrinolysis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCI following fibrinolysis</strong> – Our preference for UFH in patients undergoing PCI is supported by the similar clinical effect of UFH compared with other anticoagulants in fibrinolysis and its advantages in patients treated with primary PCI. (See <a class="local">'Evidence in primary PCI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinolysis without PCI</strong> –<strong> </strong>In patients with STEMI who are primarily treated with fibrinolysis without subsequent PCI, the available evidence suggests that anticoagulation with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> have a greater effect than no anticoagulation or anticoagulation with other agents. <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> is not well studied in this setting and may be associated with greater rates of intracerebral hemorrhage. Trials that describe the effects of the various anticoagulants compared with no anticoagulation or with other agents include the following:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of anticoagulation versus no anticoagulation</strong> –<strong> </strong>The trials and studies that compare anticoagulation with no anticoagulation include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UFH compared with placebo</strong> – In trials of patients with STEMI who underwent primary fibrinolysis, treatment with heparin was associated with minimal or no benefit on mortality when compared with placebo, and the effect of heparin on vessel patency varied between trials. There are no randomized trials that directly compare heparin with placebo in patients optimally treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus a platelet P2Y<sub>12</sub> inhibitor, which is a major limitation of the available data. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Patients receiving fibrinolytic therapy'</a>.)</p><p></p><p class="bulletIndent1">The data that support the use of heparin as an adjunctive therapy in patients undergoing fibrinolysis include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a 2005 meta-analysis of four trials that studied the relative effect of UFH with placebo, there were similar rates of mortality (4 versus 5 percent in the placebo group; pooled odds ratio [OR] 1.04, 95% CI 0.62-1.8) and reinfarction (3.5 versus 3.2 percent, pooled OR 1.1, 95% CI 0.6-2.0) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Though fibrin-specific agents (eg, <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">tenecteplase</a>, <a class="drug drug_general" data-topicid="9857" href="/z/d/drug information/9857.html" rel="external">reteplase</a>) might result in more circulating fibrin and thrombosis when compared with non-fibrin-specific agents (eg, streptokinase), the effect of UFH on mortality and vessel patency was minimal or none for both types of agents [<a href="#rid16">16-21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LMWH compared with placebo</strong> –<strong> </strong>The effect of low molecular weight heparin (LMWH) has been evaluated in clinical trials of patients with STEMI who were predominantly treated with streptokinase; it is unclear whether the results of LMWH extend to patients treated with <a class="drug drug_general" data-topicid="9955" href="/z/d/drug information/9955.html" rel="external">tenecteplase</a> and <a class="drug drug_general" data-topicid="9857" href="/z/d/drug information/9857.html" rel="external">reteplase</a> (ie, the preferred agents for thrombolysis)  (<a class="graphic graphic_table graphicRef56744" href="/z/d/graphic/56744.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a meta-analysis of trials that compared UFH and LMWH with placebo, LMWH was associated with a lower risk of death at 30 days (10 versus 11 percent; pooled OR 0.86, 95% CI 0.78-0.95) and reinfarction (1.6 versus 2.1 percent; pooled OR 0.72, 95% CI 0.58-0.90) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the largest trial included in the meta-analysis, the CREATE trial, patients with an acute STEMI were randomly assigned to reviparin or placebo [<a href="#rid22">22</a>]. Streptokinase was the most administered agent in this trial (73 percent of patients). At seven days, the rate of the primary composite outcome (death, MI, or stroke) was significantly reduced with reviparin (9.6 versus 11.0 percent; hazard ratio [HR] 0.87, 95% CI 0.79-0.95), and this benefit persisted at 30 days. Reviparin treatment was significantly better when started within two hours after symptom onset.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fondaparinux</strong><strong> compared with placebo</strong> – The efficacy of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in STEMI was evaluated in the OASIS-6 trial [<a href="#rid14">14</a>]. The trial was designed to assess the effect of fondaparinux relative to "usual care" in a group of patients without an indication for anticoagulation (eg, non-fibrin-specific fibrinolytic agent, no PCI) and in another group of patients with an indication for anticoagulation (eg, fibrin-specific thrombolytic agent, reperfusion with primary PCI):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Stratum 1 consisted of 5658 patients who did not have an indication for anticoagulation as determined by the treating clinician. These patients mostly received primary reperfusion with streptokinase (78 percent) and were randomly assigned to subcutaneous <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> (initial dose intravenously and then 2.5 mg/day given subcutaneously) or placebo for up to eight days or hospital discharge, whichever occurred first. In this arm of the trial, fondaparinux was associated with a lower rate of the primary endpoint of death or reinfarction (11.2 versus 14.0 percent; HR 0.79, 95% CI 0.68-0.92). The results of stratum 2 are described below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relative efficacy of the anticoagulants</strong> – Among agents used as adjunctive therapy in fibrinolysis, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> may be the most effective but is more difficult to manage in patients who will undergo PCI as part of a pharmacoinvasive strategy  (<a class="graphic graphic_algorithm graphicRef138821" href="/z/d/graphic/138821.html" rel="external">algorithm 1</a>). In the absence of a large benefit of anticoagulation, the complications of dosing enoxaparin, and sheath thrombus associated with <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, UFH has several advantages over other anticoagulants and can be used among patients who will undergo a pharmacoinvasive strategy. In patients who will not undergo PCI, fondaparinux and enoxaparin have greater efficacy when compared with UFH.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UFH compared with LMWH</strong> – Trials and studies that compared the relative efficacy of UFH and LMWH (<a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>) in patients with STEMI treated with fibrinolytic agents have generally found that enoxaparin is superior to UFH [<a href="#rid23">23-28</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A 2007 meta-analysis of trials comparing UFH to <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> in over 27,000 STEMI patients receiving fibrinolytic therapy found that the primary outcome of death, MI, or major bleeding at 30 days occurred less often in patients receiving enoxaparin (11.1 versus 12.9 percent, OR 0.84, 95% CI 0.73-0.97), with most of the benefit attributable to a reduction in MI [<a href="#rid29">29</a>]. However, major bleeding occurred significantly more often in patients receiving enoxaparin (2.6 versus 1.8 percent).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A substudy of ExTRACT-TIMI 25, which was published after the meta-analysis, included 4676 patients who underwent fibrinolysis, some of whom underwent subsequent PCI [<a href="#rid30">30</a>]. Compared with patients assigned to UFH, patients who were randomly assigned to <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> had a lower rate of provisional PCI (an indicator of failed fibrinolysis; 23 versus 24 percent) and, among those who underwent PCI, a lower rate of the primary endpoint (11 versus 14 percent). There were no differences in major bleeding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fondaparinux</strong><strong> compared with UFH</strong> – In stratum 2 of the OASIS-6 trial, 6434 patients who had an indication for heparin (eg, fibrinolytic therapy with a fibrin-specific agent, planned PCI) as determined by the treating clinician were randomly assigned to <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> (initial dose intravenously and then 2.5 mg/day given subcutaneously) for up to eight days or hospital discharge, or to UFH 60 units/kg bolus followed by infusion of 12 units/kg/hour for 24 to 48 hours [<a href="#rid14">14</a>]. In patients assigned to fondaparinux, there was a small decrease in the rate of the primary outcome (8.3 versus 8.7 percent; HR 0.96, 95% CI 0.76-0.99).</p><p></p><p class="bulletIndent2">In prespecified subgroup analyses that included all patients enrolled in OASIS-6, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> was beneficial in patients who received fibrinolytic therapy with PCI or who received no reperfusion therapy. However, in patients who received fondaparinux and who underwent PCI, there was a higher rate of the primary outcome and sheath thrombosis [<a href="#rid31">31,32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bivalirudin</strong><strong> compared with UFH</strong> – <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> was compared with UFH in the HERO-2 trial of 17,073 STEMI patients treated with streptokinase [<a href="#rid33">33</a>]. At 30 days, the rates of mortality were similar between the two groups (11 percent) and there was a small reduction in reinfarction at 96 hours with bivalirudin (1.6 versus 2.3 percent). In addition, there was some evidence that the risk of severe bleeding (0.7 versus 0.5 percent) and intracerebral bleeding (0.6 versus 0.4 percent) were higher with bivalirudin, and moderate and mild bleeding were increased with bivalirudin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other anticoagulants</strong> – There are only limited data assessing the role of <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> or lepirudin [<a href="#rid34">34</a>]; these drugs are not used in acute STEMI due to the absence of large-scale trials showing benefit and concerns of an increased rate of bleeding compared with other anticoagulants.</p><p></p><p class="headingAnchor" id="H15"><span class="h1">NO REPERFUSION THERAPY</span></p><p class="headingAnchor" id="H278063802"><span class="h2">Choice of agent</span><span class="headingEndMark"> — </span>For patients who do not undergo reperfusion with primary percutaneous coronary intervention (PCI) or fibrinolysis and who do not have contraindications to anticoagulation or another indication for long-term anticoagulation (eg, mechanical valve), we suggest treatment with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) for 48 hours or with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> for eight days or until discharge, whichever comes first  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>). We do not use <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in this setting.</p><p>The American College of Cardiology/American Heart Association guidelines suggest that the approach to anticoagulation for patients not undergoing reperfusion is generally the same as that for patients undergoing reperfusion [<a href="#rid4">4,5</a>]. The European Society of Cardiology guidelines note that anticoagulation should be given to patients who will not undergo reperfusion and contains a weak recommendation for <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> rather than UFH or <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1901780016"><span class="h2">Dosing and monitoring</span><span class="headingEndMark"> — </span>The dosing and monitoring of each agent are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>UFH</strong> – For patients treated with medical therapy (no reperfusion), we suggest an intravenous (IV) bolus of 50 to 70 units/kg up to a maximum of 5000 units, to be followed by an IV drip of 12 units/kg/hour, with a goal activated partial thromboplastin time of 1.5 to 2 times control or approximately 50 to 75 s.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enoxaparin</strong> – The dosing of <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> is based on age and kidney function, and monitoring is not typically required:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age less than 75 years</strong> –<strong> </strong>In patients who are &lt;75 years of age with creatinine clearance ≥30 mL/minute using the Cockcroft-Gault formula (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>), we use a loading dose of 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours (maximum of 100 mg for the first two doses only). The first subcutaneous dose should be administered with the IV bolus.</p><p></p><p class="bulletIndent2">For patients who are &lt;75 years of age with a creatinine clearance &lt;30 mL/minute using the Cockcroft-Gault formula, we use a 30 mg IV bolus given with the first dose of the subcutaneous maintenance regimen, which is adjusted to 1 mg/kg subcutaneously every 24 hours.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age ≥75 years</strong> – In patients ≥75 years with creatinine clearance ≥30 mL/minute, we do not use a loading dose and administer a maintenance dose of 0.75 mg/kg subcutaneously every 12 hours (maximum of 75 mg for the first two doses only).</p><p></p><p class="bulletIndent2">For patients who are 75 years or older with a creatinine clearance &lt;30 mL/minute, we do not use a loading dose and administer a maintenance subcutaneous dose of 1 mg/kg every 24 hours.</p><p></p><p class="headingAnchor" id="H3783205405"><span class="h2">Evidence</span><span class="headingEndMark"> — </span>Our recommendation for anticoagulant use in this setting is largely based on the pathophysiology of thrombus formation in acute MI and from extrapolation of the experience with patients who undergo reperfusion to patients who will not undergo reperfusion. The available studies of anticoagulation versus no anticoagulation in this population have conflicting results. Only one relatively small trial directly compared UFH with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> and found similar event rates between the two groups:</p><p class="bulletIndent1"><span class="glyph">●</span>From subgroup analyses of trials designed to assess the efficacy of fibrinolysis, patients treated with heparin alone (eg, did not receive a thrombolytic) did not clearly have a lower risk of adverse outcomes when compared with placebo.</p><p></p><p class="bulletIndent1">For example, in a subgroup analysis of 3325 patients who did not undergo thrombolysis as intended in the CREATE trial, therapy with reviparin was associated with a significant reduction in the incidence of death, MI, or stroke compared with placebo (15 versus 18 percent) [<a href="#rid22">22</a>], while the results of other studies showed conflicting results [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The TETAMI trial compared the efficacy of UFH (with or without <a class="drug drug_general" data-topicid="10288" href="/z/d/drug information/10288.html" rel="external">tirofiban</a>) with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> (with or without tirofiban) in 1224 patients who were ineligible for reperfusion therapy [<a href="#rid38">38</a>]. At 30 days, the incidence of the combined endpoint of death, reinfarction, or recurrent angina for patients treated with enoxaparin was similar to UFH (16 versus 17 percent).</p><p></p><p>In patients who did not receive reperfusion, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> has not been studied and the only evidence for the efficacy of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> is from a subgroup analysis:</p><p class="bulletIndent1"><span class="glyph">●</span>The role of <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in patients with STEMI not treated with reperfusion was evaluated in a prespecified subgroup analysis of the OASIS-6 trial (see <a class="local">'Rationale and evidence in primary fibrinolysis'</a> above). Among the 2867 in the trial who did not undergo reperfusion therapy, fondaparinux reduced the rate of the primary efficacy outcome (death and MI at 30 days) compared with UFH or placebo (12.2 versus 15.1 percent; hazard ratio 0.80, 95% CI 0.65-0.98) [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H2252305497"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation for primary PCI</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulation prior to PCI</strong> – Patients with ST-elevation myocardial infarction (STEMI) whose reperfusion strategy is primary percutaneous coronary intervention (PCI)  (<a class="graphic graphic_algorithm graphicRef138821" href="/z/d/graphic/138821.html" rel="external">algorithm 1</a>) require prompt anticoagulation  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>). The only exceptions to immediate anticoagulation are cases in which the process of starting anticoagulation would delay primary PCI (eg, delay transfer to a PCI-capable center, delay the PCI procedure).</p><p></p><p class="bulletIndent2">For most patients with STEMI who will undergo primary PCI, we suggest initial anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) rather than other agents (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>)  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer UFH over enoxaparin because UFH has simpler dosing and monitoring. Bivalirudin has not been studied in this setting. (See <a class="local">'Anticoagulation prior to PCI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulation during PCI</strong> – All patients who undergo PCI require anticoagulation to prevent intraarterial thrombus formation. During PCI for STEMI, we suggest UFH or <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> rather than other anticoagulants (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>)  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice between UFH and bivalirudin is individualized and is largely based on the cardiologist’s preference (eg, UFH is easier to monitor than bivalirudin, bivalirudin requires a longer duration of infusion than UFH).</p><p></p><p class="bulletIndent2">If <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> was given &gt;6 hours prior to PCI, we initiate UFH during PCI rather than maintain anticoagulation with enoxaparin. We do not use <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> because it is associated with increased risk of catheter thrombosis. (See <a class="local">'Anticoagulation during PCI'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticoagulation after PCI</strong> –<strong> </strong>The duration of anticoagulation is influenced by the agent used, whether complications occurred during PCI, and whether there is an indication for long-term anticoagulation. (See <a class="local">'Anticoagulation after PCI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation for fibrinolysis with or without PCI</strong> – In patients with STEMI who undergo reperfusion with fibrinolysis regardless of the specific fibrinolytic agent  (<a class="graphic graphic_algorithm graphicRef138821" href="/z/d/graphic/138821.html" rel="external">algorithm 1</a>), the approach to anticoagulation is influenced by the likelihood of angiography and/or PCI following fibrinolysis as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrinolysis followed by PCI</strong> – In patients who undergo primary fibrinolysis and who are likely to have PCI thereafter (ie, pharmacoinvasive strategy), we suggest the use of UFH rather than other agents (eg, <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a>, or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>)  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fibrinolysis without planned PCI</strong> –<strong> </strong>For patients who are unlikely to undergo angiography and/or PCI, we suggest anticoagulation with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> rather than other agents or no anticoagulation  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). However, fondaparinux is not approved for use in patients with STEMI by the US Food and Drug Administration. (See <a class="local">'Choice of anticoagulant'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – The duration of therapy is determined by the agent:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>UFH</strong> – UFH therapy should continue with periodic monitoring according to local protocols until PCI is complete or for 48 hours, whichever comes first. (See <a class="local">'Dosing and duration of therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Enoxaparin</strong> – For patients who will undergo PCI and who are treated with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a>, therapy with enoxaparin should continue until PCI. For patients who will not undergo PCI, therapy with enoxaparin should continue for eight days or until discharge, whichever comes first. (See <a class="local">'Dosing and duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation if no reperfusion therapy</strong> – For patients who do not undergo reperfusion with primary PCI or fibrinolysis and who do not have contraindications to anticoagulation or another indication for long-term anticoagulation (eg, mechanical valve), we suggest treatment with UFH for 48 hours or with <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">enoxaparin</a> for eight days or until discharge, whichever comes first  (<a class="graphic graphic_algorithm graphicRef139386" href="/z/d/graphic/139386.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We do not use <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> or <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> in this setting. (See <a class="local">'No reperfusion therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.</a></li><li><a class="nounderline abstract_t">Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med 2015; 373:997.</a></li><li><a class="nounderline abstract_t">Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet 2022; 400:1847.</a></li><li><a class="nounderline abstract_t">Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.</a></li><li><a class="nounderline abstract_t">Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.</a></li><li><a class="nounderline abstract_t">Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119.</a></li><li><a class="nounderline abstract_t">Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med 2017; 377:1132.</a></li><li><a class="nounderline abstract_t">Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384:1849.</a></li><li><a class="nounderline abstract_t">Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369:2207.</a></li><li><a class="nounderline abstract_t">Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218.</a></li><li><a class="nounderline abstract_t">Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378:693.</a></li><li><a class="nounderline abstract_t">Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011; 9:1902.</a></li><li><a class="nounderline abstract_t">Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344:e553.</a></li><li><a class="nounderline abstract_t">Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112:3855.</a></li><li><a class="nounderline abstract_t">GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615.</a></li><li><a class="nounderline abstract_t">O'Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994; 23:11.</a></li><li><a class="nounderline abstract_t">de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67:122.</a></li><li><a class="nounderline abstract_t">Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990; 323:1433.</a></li><li><a class="nounderline abstract_t">Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79:281.</a></li><li><a class="nounderline abstract_t">Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991; 83:1534.</a></li><li><a class="nounderline abstract_t">Yusuf S, Mehta SR, Xie C, et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293:427.</a></li><li><a class="nounderline abstract_t">Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104:648.</a></li><li><a class="nounderline abstract_t">Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605.</a></li><li><a class="nounderline abstract_t">Van de Werf F. ASSENT-3: implications for future trial design and clinical practice. Eur Heart J 2002; 23:911.</a></li><li><a class="nounderline abstract_t">Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105:1642.</a></li><li><a class="nounderline abstract_t">Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135.</a></li><li><a class="nounderline abstract_t">Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477.</a></li><li><a class="nounderline abstract_t">Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007; 28:2077.</a></li><li><a class="nounderline abstract_t">Gibson CM, Murphy SA, Montalescot G, et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49:2238.</a></li><li><a class="nounderline abstract_t">Oldgren J, Wallentin L, Afzal R, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008; 29:315.</a></li><li><a class="nounderline abstract_t">Peters RJ, Joyner C, Bassand JP, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008; 29:324.</a></li><li><a class="nounderline abstract_t">White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358:1855.</a></li><li><a class="nounderline abstract_t">Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33:1879.</a></li><li><a class="nounderline abstract_t">Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.</a></li><li><a class="nounderline abstract_t">Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.</a></li><li><a class="nounderline abstract_t">Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342:759.</a></li><li><a class="nounderline abstract_t">Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003; 42:1348.</a></li></ol></div><div id="topicVersionRevision">Topic 92 Version 68.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087958" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Direct thrombin inhibitors in cardiovascular medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26324049" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36351459" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19942100" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886621" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844201" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002178" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24171490" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bivalirudin started during emergency transport for primary PCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499566" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bivalirudin during primary PCI in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856483" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777368" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306479" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537725" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344381" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232430" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8277068" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1540431" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2122251" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492454" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902404" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671427" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489769" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11530146" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069439" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ASSENT-3: implications for future trial design and clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940541" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847070" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537665" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17600038" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560287" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084015" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245119" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11741625" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362188" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922416" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2899772" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8103874" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14563573" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
